Becton, Dickinson and Company (BDX) Stock Analysis
“New BD” emerges as a higher-margin, connected-care and biologics-delivery pure-play—executing through tariff and regulatory headwinds while the market still prices it like the old conglomerate.
Overview
As of May 2026, BD has completed a major transformation into “New BD,” a leaner, medtech-focused company after divesting its Biosciences and Diagnostic Solutions businesses and eliminating the legacy Life Sciences segment. The reconfigured company is organized into Medical Essentials (scale consumables), Connected Care (infusion + monitoring), BioPharma Systems (drug delivery), and Interventional (specialty surgery/chronic care). Q2 FY26 results were the first comprehensive read-through post-transaction and showed solid momentum: revenue of $4.714B (+5.2% reported; +2.6% FX-neutral) and adjusted EPS of $2.90, beating consensus and supporting a raise in full-year guidance. Margins dipped on tariff/mix headwinds, but BD Excellence productivity and cost-out execution are cushioning profitability while management prioritizes capital returns and debt reduction.